A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 47/48 (2006.01) A61K 38/37 (2006.01) A61P 7/04 (2006.01) C07K 14/755 (2006.01) C07K 17/08 (2006.01)
Patent
CA 2726942
This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties in subjects lacking von Willebrand Factor.
Cette invention concerne le traitement de la maladie de von Willebrand par administration de mutéines du facteur VIII qui sont liées par covalence, à un site prédéfini qui nest pas une amine à terminaison N, à un ou plusieurs polymères biocompatibles tels que le polyéthylène glycol. Les conjugués de mutéine conservent lactivité procoagulante du FVIII et présentent des propriétés pharmacocinétiques améliorées chez des sujets dépourvus de facteur de von Willebrand.
Jiang Haiyan
Liu Tongyao
Murphy John E.
Pan Junliang
Pierce Glenn
Bayer Healthcare Llc
Mbm Intellectual Property Law Llp
LandOfFree
Fviii muteins for treatment of von willebrand disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fviii muteins for treatment of von willebrand disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fviii muteins for treatment of von willebrand disease will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1861013